Table 1 Comparison of patient characteristics between the AZA-001 trial and the EORTC 0611 trial for high-risk MDS
From: A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
AZA-001 trial: azacitidine | EORTC 0611 trial: decitabine | |
|---|---|---|
Eligibility criteria | IPSS INT2/high | IPSS INT1/INT2/high |
MDS with 5–30 % blasts | MDS with 11–30 % blasts or <10 % blasts and poor cytogenetics | |
CMML with >10 % blasts and WBC <13 G/L | CMML independent of blast counts or WBC counts | |
No t-MDS allowed | t-MDS allowed | |
Treatment schedule | 75 mg/m2 days 1–7, q28 | 15 mg/m2 3× day q42 |
Treatment until progression | Maximum number of 8 cycles | |
Patient cohort | ||
IPSS high | 46 % | 38.70 % |
Poor cytogenetics | 28 % | 48 % |
t-MDS | 0 | 12.60 % |
Median cycle number | 9 | 4 |